Share chart GlaxoSmithKline
Extended chart
Simple chart
About GlaxoSmithKline
GlaxoSmithKline plc вместе со своими дочерними компаниями занимается созданием, открытием, разработкой, производством и маркетингом фармацевтических продуктов, вакцин, безрецептурных лекарств и потребительских товаров для здоровья в Великобритании, США и на международном уровне. Он работает в четырех сегментах: фармацевтика, исследования и разработки в фармацевтике, вакцины и здравоохранение. more detailsMain settings
IPO date
1986-07-09
ISIN
US37733W2044
Industry
Pharmaceuticals
Sector
Health Care
Валюта
usd
Валюта отчета
gbp
Див.доход ао
4.01
Дивиденд ао
0.429
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 1.77 | 8 |
| P/BV | 4.24 | 4 |
| P/E | 21.56 | 7 |
Efficiency
| Title | Value | Grade |
| ROA | 4.35 | 1 |
| ROE | 19.06 | 6 |
| ROIC | 12.84 | 4 |
Dividends
| Title | Value | Grade |
| Dividend yield | 3.99 | 9.98 |
| DSI | 0.7857 | 7.86 |
| Average dividend growth | -2.24 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | 2.55 | 5 |
| Debt/Ratio | 0.2857 | 10 |
| Debt/Equity | 1.24 | 8 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | -7.99 | 0 |
| Yield Ebitda, % | -21.4 | 0 |
| Yield EPS, % | -67.19 | 0 |
Dividends
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 42.49 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 41.2 $ | 40.86 $ | 42.49 $ | 3.13 % | 0 % | 0 % |
| Month | 38.92 $ | 37.64 $ | 42.49 $ | 9.17 % | 0 % | 0 % |
| Three month | 34.48 $ | 33.6 $ | 42.49 $ | 23.23 % | 0 % | 0 % |
| Half a year | 34.84 $ | 32.08 $ | 42.49 $ | 21.96 % | 0 % | 0 % |
| Year | 43.9 $ | 32.08 $ | 44.26 $ | -3.21 % | 0 % | 0 % |
| 3 years | 31.47 $ | 28.66 $ | 45.78 $ | 35.02 % | 0 % | 0 % |
| 5 years | 35.77 $ | 28.66 $ | 46.73 $ | 18.79 % | 0 % | 0 % |
| 10 years | 33.23 $ | 28.23 $ | 47.89 $ | 27.88 % | 0 % | 0 % |
| Year to date | 36.17 $ | 32.08 $ | 42.49 $ | 17.47 % | 0 % | 0 % |
Insider trading
Main owners
Contained in ETF
| ETF | Share, % | Profitability for 1 year, % | Commission, % |
| SPDR Solactive United Kingdom ETF | 3.6 | 50.67 | 0.14 |
| Pacer BioThreat Strategy ETF | 2.84213 | 6.83 | 0.7 |
| Barclays ETN+ FI Enhanced Europe 50 ETN Series C | 2.37 | 0 | 1.05 |
| AAM S&P Developed Markets High Dividend Value ETF | 1.88686 | 2.67 | 0.39 |
| VanEck Morningstar Global Wide Moat ETF | 1.78619 | 11.32 | 0.52 |
| Pacific Global International Equity Income ETF | 1.72 | 0 | 0.39 |
| FCF International Quality ETF | 1.64717 | -1.15 | 0.59 |
| Nuveen Global Net Zero Transition ETF | 1.28105 | 0.4268 | 0.56 |
| Knowledge Leaders Developed World ETF | 1.24702 | -2.72 | 0.75 |
| Credit Suisse FI Enhanced Europe 50 ETN | 0.93 | 49.45 | 2.00 |
| FlexShares International Quality Dividend Defensive Index Fund | 0.7774 | -7.89 | 0.47 |
| E-TRACS UBS Bloomberg CMCI Food ETN | 0.49648 | 17.97 | 0.65 |
| Fidelity New Millennium ETF | 0.33039 | -6.7 | 0.38 |
| IQ 500 International ETF | 0.32773 | -4.21 | 0.25 |
| VictoryShares Developed Enhanced Volatility Wtd ETF | 0.23444 | 0.8332 | 0.51 |
| 1.43 | 7.83 | 0.62 |
|---|
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Ms. Sarah Elton-Farr | Head of Investor Relations | N/A | |
| Mr. James Ford | Senior VP & Group General Counsel of Legal & Compliance | N/A | |
| Ms. Sally Jackson | Senior Vice President of Global Communications & CEO Office | N/A | |
| Ms. Diana Conrad | Chief People Officer | N/A | |
| Ms. Shobie Ramakrishnan | Chief Digital & Technology Officer | N/A | 1971 (54 years) |
| Ms. Emma Natasha Walmsley | CEO & Director | 6.82M | 1969 (56 years) |
| Mr. Tony Wood | Chief Scientific Officer and Head of R&D | N/A | |
| Mr. David Simon Redfern BSc (Hons), CA | President of Corporate Development | N/A | 1966 (59 years) |
| Mr. Philip C. Thomson | President of Global Affairs | N/A | |
| Ms. Julie Belita Brown | CFO & Executive Director | 6.51M | 1962 (63 years) |
About company
Address: United Kingdom, Brentford, 980 Great West Road - Open in google maps, Open in yandex maps
Website: https://www.gsk.com
Website: https://www.gsk.com
